Incidence, characteristics, and management of recently diagnosed, microscopically invasive breast cancer by receptor status: Iowa SEER 2000 to 2013

Alexandra Thomas; Ronald J Weigel; Charles F Lynch; Philip M Spanheimer; Elizabeth K Breitbach; Mary C Schroeder

doi:10.1016/j.amjsurg.2016.08.008

Back

Incidence, characteristics, and management of recently diagnosed, microscopically invasive breast cancer by receptor status: Iowa SEER 2000 to 2013

Journal article

Peer reviewed

Incidence, characteristics, and management of recently diagnosed, microscopically invasive breast cancer by receptor status: Iowa SEER 2000 to 2013

Alexandra Thomas, Ronald J Weigel, Charles F Lynch, Philip M Spanheimer, Elizabeth K Breitbach and Mary C Schroeder

The American journal of surgery, Vol.214(2), pp.323-328

08/2017

DOI: 10.1016/j.amjsurg.2016.08.008

PMCID: PMC5334458

PMID: 27692792

Files and links (1)

url

https://www.ncbi.nlm.nih.gov/pmc/articles/5334458View

Open Access

Abstract

Recent incidence, treatment patterns, and outcomes for node negative microscopically invasive breast cancer (MIBC) have not been reported. State Health Registry of Iowa data identified women with ductal carcinoma in situ (DCIS), MIBC, and stage I breast cancer excluding MIBC (stage 1BC). From 2000 to 2013, 1,706, 193, and 4,514 women were diagnosed with DCIS, MIBC, and stage 1BC, respectively. MIBC increased at an annual percentage change of 2.1 (P = .041). MIBC was more frequently human epidermal growth factor receptor 2 positive than stage 1BC (39.7% vs 9.6%, P < .001). Mastectomy was performed more frequently in MIBC than DCIS (40.9% vs 30.6%, P = .014) or stage 1BC (40.9% vs 33.8%, P = .119). Chemotherapy was given to 4.1% of women with MIBC. Survival for women with MIBC was intermediate between DCIS and stage 1BC. Management of MIBC is an increasingly frequent clinical scenario. Women with MIBC receive more aggressive local and systemic therapy than women with DCIS. •Microscopically invasive breast cancer (MIBC) is increasing in incidence.•HER2–positive breast cancer is overrepresented in MIBC.•More women with MIBC received mastectomy and chemotherapy than women with DCIS.•Survival with MIBC is intermediate between DCIS and other stage 1 disease.

Microinvasive tumor

Mastectomy

Cancer incidence

Breast neoplasms

SEER program

Details

Title: Subtitle: Incidence, characteristics, and management of recently diagnosed, microscopically invasive breast cancer by receptor status: Iowa SEER 2000 to 2013
Creators: Alexandra Thomas - Division of Hematology, Oncology and Blood and Marrow Transplantation, Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA, USA
Ronald J Weigel - Department of Surgery, Carver College of Medicine, University of Iowa, Iowa City, IA, USA
Charles F Lynch - Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA, USA
Philip M Spanheimer - Department of Surgery, Carver College of Medicine, University of Iowa, Iowa City, IA, USA
Elizabeth K Breitbach - Carver College of Medicine, University of Iowa, Iowa City, IA, USA
Mary C Schroeder - Division of Health Services Research, Department of Pharmacy Practice and Science, College of Pharmacy, University of Iowa, Iowa City, IA, USA
Resource Type: Journal article
Publication Details: The American journal of surgery, Vol.214(2), pp.323-328
DOI: 10.1016/j.amjsurg.2016.08.008
PMID: 27692792
PMCID: PMC5334458
NLM abbreviation: Am J Surg
ISSN: 0002-9610
eISSN: 1879-1883
Publisher: Elsevier Inc
Grant note: P30 CA086862 / Cancer Center Support National Cancer Institute (http://dx.doi.org/10.13039/100000054)
Language: English
Date published: 08/2017
Academic Unit: Molecular Physiology and Biophysics; Anatomy and Cell Biology; Epidemiology; Surgery; Pharmacy Practice and Science; Biochemistry and Molecular Biology; Internal Medicine
Record Identifier: 9983995052002771

Metrics

15 Record Views

9 Times Cited - Web of Science